Effect of Coenzyme Q10 on echocardiographic parameters

Effect of Coenzyme Q10 on echocardiographic parameters in patients with heart failure due to dilated cardiomyopathy

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190612043878N1

Enrollment

Registered

2021-04-14

Start date

2020-08-22

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congestive Heart Failure. Heart failure

Interventions

Intervention group: Patients will be treated with coenzyme Q10 1 mg (Golden Life, Australia), orally daily for 2 months..

Eligibility

Sex/Gender

All

Age

No minimum to 15 Years

Inclusion criteria

Inclusion criteria: Children with heart failure due to dilated cardiomyopathy

Exclusion criteria

Exclusion criteria: Metabolic diseases Other cardiac diseases

Design outcomes

Primary

Measure	Time frame
Ejection fraction. Timepoint: 2 months. Method of measurement: Echocardiography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmirhosseinZarepur

Bandare-abbas University of Medical Sciences

dr.amirhosseinzarepur@gmail.com+98 35 3624 5341

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026